Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Sutro Biopharma Inc (STRO)

Sutro Biopharma Inc (STRO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 258,510
  • Shares Outstanding, K 62,442
  • Annual Sales, $ 153,730 K
  • Annual Income, $ -106,790 K
  • 60-Month Beta 0.95
  • Price/Sales 1.68
  • Price/Cash Flow N/A
  • Price/Book 1.83
Trade STRO with:

Options Overview Details

View History
  • Implied Volatility 155.06% ( +23.97%)
  • Historical Volatility 120.75%
  • IV Percentile 92%
  • IV Rank 60.37%
  • IV High 251.36% on 03/20/24
  • IV Low 8.38% on 06/16/23
  • Put/Call Vol Ratio 0.50
  • Today's Volume 78
  • Volume Avg (30-Day) 78
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 1,277
  • Open Int (30-Day) 883

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.88
  • Number of Estimates 7
  • High Estimate -0.72
  • Low Estimate -1.02
  • Prior Year -0.76
  • Growth Rate Est. (year over year) -15.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.20 +29.37%
on 03/20/24
6.13 -32.46%
on 03/28/24
-0.29 (-6.55%)
since 03/12/24
3-Month
3.20 +29.37%
on 03/20/24
6.13 -32.46%
on 03/28/24
+0.14 (+3.50%)
since 01/12/24
52-Week
2.01 +106.48%
on 11/13/23
6.13 -32.46%
on 03/28/24
-0.11 (-2.59%)
since 04/12/23

Most Recent Stories

More News
Synlogic, Inc. (SYBX) Reports Q1 Loss, Lags Revenue Estimates

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 8% and 3.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

SYBX : 1.7700 (+1.14%)
STRO : 4.14 (-8.00%)
Sutro Biopharma, Inc. (STRO) Soars 11.3%: Is Further Upside Left in the Stock?

Sutro Biopharma, Inc. (STRO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price...

STRO : 4.14 (-8.00%)
XENE : 41.30 (-3.89%)
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?

IDEAYA Biosciences, Inc. (IDYA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IDYA : 41.97 (-3.43%)
STRO : 4.14 (-8.00%)
Sutro Biopharma, Inc. (STRO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Sutro Biopharma, Inc. (STRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

STRO : 4.14 (-8.00%)
PRQR : 2.20 (-4.35%)
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Misses Revenue Estimates

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 4.69% and 24.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

STRO : 4.14 (-8.00%)
RETA : 172.36 (+0.02%)
Adma Biologics (ADMA) Reports Q4 Loss, Tops Revenue Estimates

Adma Biologics (ADMA) delivered earnings and revenue surprises of 14.29% and 1.96%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ADMA : 6.02 (-3.22%)
STRO : 4.14 (-8.00%)
How Much Upside is Left in Sutro Biopharma, Inc. (STRO)? Wall Street Analysts Think 214%

The average of price targets set by Wall Street analysts indicates a potential upside of 213.8% in Sutro Biopharma, Inc. (STRO). While the effectiveness of this highly sought-after metric is questionable,...

STRO : 4.14 (-8.00%)
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -146.67% and 121.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

STRO : 4.14 (-8.00%)
TELA : 4.92 (-0.51%)
Sutro Biopharma, Inc. (STRO) Expected to Beat Earnings Estimates: Should You Buy?

Sutro Biopharma, Inc. (STRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

STRO : 4.14 (-8.00%)
HSKA : 119.99 (+0.04%)
GSK (GSK) Q3 Earnings and Revenues Beat Estimates

Glaxo (GSK) delivered earnings and revenue surprises of 21.11% and 18.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

GSK : 40.66 (-0.34%)
STRO : 4.14 (-8.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in...

See More

Key Turning Points

3rd Resistance Point 4.78
2nd Resistance Point 4.62
1st Resistance Point 4.38
Last Price 4.14
1st Support Level 3.98
2nd Support Level 3.81
3rd Support Level 3.57

See More

52-Week High 6.13
Fibonacci 61.8% 4.55
Last Price 4.14
Fibonacci 50% 4.07
Fibonacci 38.2% 3.58
52-Week Low 2.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar